Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
The American Journal of Managed Care27d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression ... esophageal squamous cell carcinoma (ESCC ...
Longview News-Journal19d
PD-L1 Measured by Blood Test Reveals Important Clinical Information
The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...
CURE5d
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
EurekAlert!5d
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Precision Medicine Online2d
Krazati, Keytruda Score Median Progression-Free Survival of 27 Months in First-Line NSCLC
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Business Wire16d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.
Pharmabiz2d
Immutep doses first patient in its TACTI-004 phase III clinical trial in first line non-small cell lung cancer
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...